Precisely because these two estrogen receptors have opposite effects, the imbalance in ERβ and ERα expression (low ERβ expression and high ERα expression) may be a preconditions for the occurrence and development of tumors and provide a new therapeutic target for ovarian cancer and other hormone-dependent tumors (such as breast cancer) (94). The gene discussed is ESR1; the disease is ovarian carcinoma.